| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/18/2010 | US20100041724 such as anacetrapib; cholesterol ester transfer protein inhibitors (CETP); atherosclerosis |
| 02/18/2010 | US20100041722 Organic compounds |
| 02/18/2010 | US20100041717 N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
| 02/18/2010 | US20100041715 Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof |
| 02/18/2010 | US20100041705 Organic Compounds |
| 02/18/2010 | US20100041701 Biphenyl compounds useful as muscarinic receptor antagonists |
| 02/18/2010 | US20100041695 Thieno[2,3-b]pyridines as Potassium Channel Inhibitors |
| 02/18/2010 | US20100041675 treatment of retinopathy comprising administering drugs such as tert-butyl 3-[5-ethyl-6-[4-(5,6,7,8-tetrahydro-(1,8)naphthyridin-2-yl)-piperidin-1-yl]-pyrimidin-4-ylamino]-2-(4-methoxy benzoyl)-propionate |
| 02/18/2010 | US20100041665 N-phenyl-prenylamine derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| 02/18/2010 | US20100041660 Novel 2-pyridinecarboxamide derivatives |
| 02/18/2010 | US20100041650 Purine compounds as cannabinoid receptor blockers |
| 02/18/2010 | US20100041644 Stabilized solid pharmaceutical composition of candesartan cilexetil |
| 02/18/2010 | US20100041633 Nitric oxide releasing steroids |
| 02/18/2010 | US20100041619 Lasonolide compounds as reagents for inducing premature chromosome condensation and methods for treating disorders |
| 02/18/2010 | US20100041072 Process for identifying a ligand that binds to the nep binding site for the smr1 pentapeptide |
| 02/18/2010 | US20100040675 Compositions and methods for promoting or inhibiting angiogenesis |
| 02/18/2010 | US20100040627 Baff receptor (bcma), an immunoregulatory agent |
| 02/18/2010 | US20100040617 Method of Using CD100 (or Sema4D) to Mediate Platelet Activation and Inflammatory Responses |
| 02/18/2010 | US20100040604 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha |
| 02/18/2010 | US20100040587 Cells for therapy of the heart, method of obtaining a cell preparation, and cell preparation |
| 02/18/2010 | US20100040584 Methods for promoting neovascularization |
| 02/18/2010 | US20100040581 Epo derivative-containing therapeutic agents for blood-related diseases |
| 02/18/2010 | US20100040542 Chelator conjugates |
| 02/18/2010 | CA2733970A1 Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof |
| 02/18/2010 | CA2733930A1 Anti-arrhythmia agents, methods of their use, methods of their identification, and kits therefore |
| 02/18/2010 | CA2733775A1 Agent for promoting neuronal differentiation and method therefor |
| 02/18/2010 | CA2733646A1 Acetyl pyrrolidinyl indole derivative |
| 02/18/2010 | CA2733642A1 Anti-il-12/il-23 antibodies |
| 02/18/2010 | CA2733128A1 Chymase inhibitors |
| 02/18/2010 | CA2732789A1 Treatment of pulmonary arterial hypertension |
| 02/18/2010 | CA2731370A1 Therapeutic compositions containing macitentan |
| 02/17/2010 | EP2154135A1 Therapeutic agent for cerebral infarction |
| 02/17/2010 | EP2154130A1 Pyridone compound |
| 02/17/2010 | EP2153840A1 Therapeutic agent and detection reagent for arteriosclerotic disease which targets for thallusin |
| 02/17/2010 | EP2153833A1 ADP-receptor antagonist for treatment of inflammatory disease |
| 02/17/2010 | EP2153830A1 Use of dronedarone for the preparation of a medicament intended for the prevention of stroke or transient ischemic attack |
| 02/17/2010 | EP2153736A1 Novel leukotriene receptor antagonist |
| 02/17/2010 | EP2152753A1 Antibodies against ramp3 |
| 02/17/2010 | EP2152737A2 Methods of treating, diagnosing and detecting fgf21-associated disorders |
| 02/17/2010 | EP2152701A1 Phenyl amino pyrimidine compounds and uses thereof |
| 02/17/2010 | EP2152689A1 Analogues of cilostazol |
| 02/17/2010 | EP2152683A1 Substituted amino-thiourea compounds for combating animal pests |
| 02/17/2010 | EP2152677A1 Acetamide derivatives as potassium channel modulators |
| 02/17/2010 | EP2152292A1 Angiogenesis inhibitor comprising meteorin as an active ingredient |
| 02/17/2010 | EP2152281A2 Composition for treatment of ischemic heart disease, facilitation of blood circulation and angiogenesis, improving skin beauty, improving male sexual function containing ginseng berry extract |
| 02/17/2010 | EP2152268A1 Method of treating diabetes |
| 02/17/2010 | EP1511737B1 Aryloximes |
| 02/17/2010 | EP1263954B1 Low density liprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 02/17/2010 | CN201403880Y Health-care massage antihypertensive pillow |
| 02/17/2010 | CN101648949A inhibitors of phosphatidylinositol 3-kinase |
| 02/17/2010 | CN100589839C Polypeptide and medicament composition containing polypeptide |
| 02/17/2010 | CN100589806C Use of steroid derivatives for the treatment of angiotensin II related disease e.g. cardiovascular and proliferative disorders |
| 02/16/2010 | US7662933 Pegylated granulocyte colony stimulating factor (G-CSF) to treat a hematopoietic disorder related to reduced neutrophil count, such as infectious disease, sepsis, or a result of radiotherapy or chemotherapy |
| 02/16/2010 | US7662854 HIF hydroxylase inhibitors |
| 02/16/2010 | US7662851 Use of specific cyklolignans |
| 02/16/2010 | US7662849 N-cyanomethyl-2R-[(benzenesulfonyliminomethyl)amino]-3-(2-difluoromethoxyphenylmethanesulfonyl)-propionamide; treating autoimmune disorders |
| 02/16/2010 | US7662843 Isoxazoline compounds having MIF antagonist activity |
| 02/16/2010 | US7662840 4-{5-[4-(5-Isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine or N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}-benzamidine (DW-1350); a leukotriene-B4 receptor antangonist; inhibiting osteoclastic bone absorption |
| 02/16/2010 | US7662826 Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same |
| 02/16/2010 | US7662825 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma |
| 02/16/2010 | US7662819 Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors |
| 02/16/2010 | US7662817 Psychological disorders; central nervous system disorders; antidepressants; anxiolytic agents; stress reliever; irritable bowel syndrome |
| 02/16/2010 | US7662794 DNA enzyme to inhibit plasminogen activator inhibitor-1 |
| 02/16/2010 | US7662772 Methods for treating congestive heart failure |
| 02/16/2010 | US7662633 Method of screening for inhibitors of osteopontin |
| 02/16/2010 | US7662392 Stromal-Derived Factor-1 (SDF), G-CSF (granulocyte-colony stimulating factor), stimulating vasculogenesis; improves cardiac function |
| 02/16/2010 | CA2537414C .beta. crystalline form of ivabradine chlorhydrate, process for the preparation thereof and pharmaceutical compounds containing it |
| 02/16/2010 | CA2479274C Thiazolidinedione derivatives and pharmaceutical composition comprising the same |
| 02/16/2010 | CA2478183C Substituted amides |
| 02/16/2010 | CA2452918C New compounds, which are potent inhibitors of na+/ca2+ exchange mechanism and are useful in the treatment of arrhythmias |
| 02/16/2010 | CA2450922C Piperidines for use as orexin receptor antagonists |
| 02/16/2010 | CA2445329C 20-hydroxyeicosatetraenoic acid production inhibitors |
| 02/16/2010 | CA2440037C Benzimidazole derivatives for modulating the rage receptor |
| 02/16/2010 | CA2429109C Anti-inflammatory agents |
| 02/16/2010 | CA2422267C Drying method for selectively removing volatile components from wet coatings |
| 02/16/2010 | CA2410939C Materials and methods for the treatment of gastroesophageal reflux disease |
| 02/16/2010 | CA2410399C 5-aminoalkylpyrazolo[4,3-d]pyrimidines |
| 02/16/2010 | CA2407043C Naphthamidine urokinase inhibitors |
| 02/16/2010 | CA2402436C Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |
| 02/16/2010 | CA2154231C Process for the preparation of a c1-esterase inhibitor concentrate (c1-inh) and concentrate thus obtained, for therapeutic uses |
| 02/11/2010 | WO2010017478A2 Pak1 agonists and methods of use |
| 02/11/2010 | WO2010017323A1 Novel methylenedioxy phenolic compounds and their use to treat disease |
| 02/11/2010 | WO2010017150A1 Compounds useful as inhibitors of protein kinases |
| 02/11/2010 | WO2010017105A1 Urotensin ii receptor antagonists |
| 02/11/2010 | WO2010017055A2 Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) |
| 02/11/2010 | WO2010016549A1 Tricyclic compound |
| 02/11/2010 | WO2010015939A1 Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack |
| 02/11/2010 | WO2010015870A1 Use of dihydralazine for the treatment of diseases related to elevated semicarbazide sensitive amine-oxidase (ssao) activity |
| 02/11/2010 | WO2010015792A1 Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| 02/11/2010 | WO2010015665A2 Compounds and methods |
| 02/11/2010 | WO2010015653A1 Pyrimidine derivatives as activators of soluble guanylate cyclase |
| 02/11/2010 | WO2010015586A2 2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds |
| 02/11/2010 | WO2010015585A1 6-benzyl-2,3,4,7-tetrahydro-indolo[2,3-c]quinoline compounds |
| 02/11/2010 | WO2010015447A1 Angiotensin ii receptor antagonists |
| 02/11/2010 | WO2010015335A1 Long-term treatment of symptomatic heart failure |
| 02/11/2010 | WO2010015260A2 Administration by infusion for the treatment of ischemic effects |
| 02/11/2010 | WO2010015032A1 Methods of treating and preventing glucose toxicity |
| 02/11/2010 | US20100035963 Oligoribonucleotides and Methods of use Thereof for Treatment of Cardiovascular Disease |
| 02/11/2010 | US20100035957 Methods for the Use of Inhibitors of Cytosolic Phospholipase A2 |
| 02/11/2010 | US20100035949 Microemulsion dosage forms of valsartan and methods of making the same |